European Medicines Agency recommends granting a marketing authorization for aflibercept

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Zaltrap, 25 mg/ml, concentrate for solution for infusion, intended, in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy, for the treatment of adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen. The applicant for this medicinal product is Sanofi-Aventis Groupe. Read more here.